NYSE:PFE

Pfizer Inc (PFE)

24.11
-0.61 (2.47%)
as of Jun 24, 2026, 8:37:05 pm Market Open.
581 watching
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges as it navigates a patent cliff and the subsequent impacts on revenue after its COVID-19 vaccine boom. Many analysts express concerns about the lack of earnings momentum and the uncertain prospects for new blockbuster drugs in its pipeline. Despite these challenges, PFE maintains an attractive dividend yield ranging from 6% to 7% that provides a steady income for shareholders. The company's strategy includes cost-cutting measures and acquiring smaller companies to refill its drug development pipeline. However, the stock typically trades at a low price-to-earnings ratio, indicating a lack of confidence in future growth, with multiple experts suggesting a need for patience and a potential wait for positive catalysts to drive price appreciation.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY
Top quality company. Cheap. Good sector for the long term.
BUY
Sector has been hit hard. A very liquid stock.
DON'T BUY
Governments are trying to cut health care costs. Sector seems to be weak.
BUY
US pharmaceutical sector is very cheap now.
TOP PICK
Trading at less than 20 X earnings. Reasonable dividend yield. Have some new products in the pipeline.
BUY
Looks good.
TOP PICK
Likes the valuations. Good balance sheet and good earnings. Made some good acquisitions.
HOLD
Fair market value is more than share price.
BUY
Now is a good time for drug stocks.
BUY
At a good level now.
BUY
Earnings growth is sustainable.
BUY
In the midst of a large merger.
BUY
Extremely cheap. Great product line up.
WEAK BUY
Starting to look good at $26.
DON'T BUY
Great company. Could drop further.
Showing 796 to 810 of 883 entries